Click here for the CME evaluation / post-test
Activity Index
Click on the titles below to view the presentations.
The clinical challenges in CLL today
Susan O’Brien, MD
Debate: What should be the standard of care for first line therapy of CLL?
Fludarabine-based combinations
Susan O’Brien, MD
Non-fludarabine based therapies
Martin Dyer, MD
Debate: Should biologic & molecular prognostic markers be used to assign and guide therapy for CLL patients?
Yes – Stephan Stilgenbauer, MD
No – Mark A. Weiss, MD
Debate: Is it necessary to treat to MRD negativity to achieve maximal clinical benefit in CLL?
Yes – Martin Dyer, MD
No – Alessandra Ferrajoli, MD
Emerging novel therapies for CLL
John Byrd, MD
CLL: A vision for the future cases and panel discussion
Susan O’Brien, MD
Click here for the CME evaluation / post-test
|